Editas Medicine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EDIT and other ETFs, options, and stocks.

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). 

CEO
Gilmore O’Neill
CEOGilmore O’Neill
Employees
246
Employees246
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2013
Founded2013
Employees
246
Employees246

EDIT Key Statistics

Market cap
245.48M
Market cap245.48M
Price-Earnings ratio
-0.95
Price-Earnings ratio-0.95
Dividend yield
—
Dividend yield—
Average volume
1.50M
Average volume1.50M
High today
$2.90
High today$2.90
Low today
$2.71
Low today$2.71
Open price
$2.81
Open price$2.81
Volume
1.46M
Volume1.46M
52 Week high
$4.12
52 Week high$4.12
52 Week low
$0.9101
52 Week low$0.9101

Analyst ratings

43%

of 14 ratings
Buy
42.9%
Hold
42.9%
Sell
14.3%

People also own

Based on the portfolios of people who own EDIT. This list is generated using Robinhood data, and it’s not a recommendation.
CRISPR
Intellia Therapeutics
Beam Therapeutics
Teladoc Health
Block
Pacific Biosciences
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.